U.S. markets closed

S&P Futures
4,163.75
-19.75(-0.47%)
Dow Futures
34,627.00
-41.00(-0.12%)
Nasdaq Futures
13,219.00
-137.75(-1.03%)

Yahoo Finance Plus presents 'Investing in high growth stocks during tense times'

Katie Stockton and Jared Blikre break down global stocks, bonds and cryptocurrencies on Wednesday, 5/12 at 2pm EDT.

Akebia Therapeutics, Inc. (AKBA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

2.9000-0.2200 (-7.05%)

At close: 4:00PM EDT

2.9899 +0.09 (3.10%)
After hours: 7:08PM EDT

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Momentum

Momentum

View all chart patterns

Performance Outlook

Previous Close	3.1200
Open	3.0500
Bid	2.9100 x 40700
Ask	3.0000 x 4000
Day's Range	2.8800 - 3.0700
52 Week Range	2.0900 - 13.7100
Volume	4,113,514
Avg. Volume	4,816,686

Market Cap	463.733M
Beta (5Y Monthly)	1.76
PE Ratio (TTM)	N/A
EPS (TTM)	-2.7690
Earnings Date	Aug 09, 2021 - Aug 13, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	6.71

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

Research Reports

Zacks
Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -36.36% and 19.43%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- Univar's (UNVR) Earnings Top Estimates in Q1, Sales Down Y/Y
  Zacks
- Malvern Bancorp (MLVF) Q2 Earnings Top Estimates
  Zacks
PR Newswire
Akebia Reports First Quarter 2021 Financial Results and Highlights Recent Company Milestones
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today reported financial results for the first quarter ended March 31, 2021 and highlighted recent corporate milestones. The Company will host a conference call today, Monday, May 10, 2021, at 9:00 a.m. Eastern Time.
- COMSovereign Holding Corp. Hosts First Quarter 2021 Results Conference Call on Monday, May 17, 2021 at 4:30 p.m. Eastern Time
  PR Newswire
- Intra-Cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update
  GlobeNewswire
ACCESSWIRE
Akebia Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 10, 2021 / Akebia Therapeutics, Inc. (NASDAQ:AKBA) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 10, 2021 at 9:00 AM Eastern Time.